Ex Vivo T Cell Expansion Using IL-7 and Antibody Co-Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expanding T cell populations from cord blood, such as using IL-2 and CD3/CD28 co-stimulatory beads, result in significant apoptosis and an imbalanced CD4/CD8 ratio, limiting their efficacy in treating lymphopenia and cancer, as the expanded T cells are antigen inexperienced and functionally impaired.
Innovation Solution
Contacting T cell populations with IL-7, anti-CD3, and anti-CD28 antibodies or their functional fragments to activate and expand T cells, followed by priming with IL-15, IL-12, or a combination thereof, to generate antigen-specific and tumor-specific cytotoxic T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If IL-2 and CD3/CD28 co-stimulatory beads are used to expand T cell populations, then T cell numbers increase, but significant apoptosis occurs and CD4/CD8 ratio becomes imbalanced
Solution Approach 1:
The patent changes the cytokine parameters from IL-2 to IL-7, and modifies the co-stimulation approach from CD3/CD28 beads to anti-CD3 and anti-CD28 antibodies. This parameter change resolves the contradiction by achieving T cell expansion while maintaining functional integrity and preventing apoptosis, as IL-7 signaling through the JAK-STAT pathway promotes cell survival and maintains T cell functionality during expansion
Solution Approach 2:
The patent introduces IL-7 as an intermediary cytokine that mediates T cell expansion without the harmful effects of IL-2 and bead-based co-stimulation. IL-7 acts as a survival factor and proliferation promoter that maintains the functional state of T cells, thereby serving as a beneficial intermediary that resolves the contradiction between quantity increase and functional preservation
2Quantity of substance
If cord blood T cells are expanded using conventional methods, then cell numbers increase, but the T cells become antigen inexperienced and functionally impaired
Solution Approach 1:
The patent changes the expansion parameters by using IL-7 instead of IL-2 and antibody-based co-stimulation instead of bead-based co-stimulation. These parameter changes preserve the antigen responsiveness and functional versatility of T cells during expansion, allowing them to remain adaptable to various antigens while achieving sufficient cell numbers for therapeutic use
3Quantity of substance
If more T cells are needed to treat lymphopenia, then cord blood grafts are expanded, but insufficient numbers remain after thawing and infusion
Solution Approach 1:
The patent applies preliminary expansion action by expanding T cells ex vivo before infusion using IL-7 and antibody-based co-stimulation. This preliminary expansion generates sufficient T cell numbers that can be infused to treat lymphopenia, and the functional integrity maintained by this method ensures the expanded cells remain viable and effective after infusion, thereby resolving the loss of substance problem
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves a significant increase in T cell numbers while maintaining their functional integrity and antigen responsiveness, effectively addressing lymphopenia and providing a robust anti-tumor immune response.
Implementation Method 1
contacting the T cell population with IL-7, an anti-CD3 antibody, and an anti-CD28 antibody, or functional fragments thereof, to activate and expand the T cell population
Implementation Method 2
priming a T cell population that has been expanded according to the methods herein described against an antigen in the presence of at least one of IL-15, IL-12, or IL-7, or a combination thereof
Data Source
AI summary
Provided are methods of enhancing ex vivo proliferation of a T cell population, the methods comprising contacting the T cell population with IL-7 and anti-CD3/CD28 antibody to activate and expand the T cell population. Further provided are methods of generating an antigen-specific cytotoxic T cell population comprising priming a CD3/CD28-expanded T cell population against an antigen (e.g., a cancer cell) in the presence of at least one of IL-7, IL-12, and IL-15, or a combination thereof. Further provided are methods of treating T cell lymphopenia in a subject, comprising administering a CD3/CD28-expanded T cell population to the subject.